Pricing Log in Create free account

Cardio Diagnostics Holdings, Inc. (CDIO) vs Longeveron Inc. (LGVN)

Cardio Diagnostics Holdings, Inc. and Longeveron Inc. are both Biotechnology companies. Cardio Diagnostics Holdings, Inc. and Longeveron Inc. are of similar size ($5.2M and $4.8M). Cardio Diagnostics Holdings, Inc. grew revenue faster over the last twelve months: −25.1% against −42.7%. Longeveron Inc. has the higher net margin (−1,977.6% vs −44,312.3%) and the lower return on invested capital (−4,549.0% vs −219.4%). Across the 17 metrics below, Cardio Diagnostics Holdings, Inc. leads on 11 and Longeveron Inc. on 6.

Valuation

Metric CDIO LGVN Biotechnology median
P/E n/m n/m 8.50
P/S 342.57 3.67 9.71
P/B 0.67 0.42 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.10 0.22 0.64
EV/Sales (40.08) (4.16) 9.21
Earnings yield (172.78%) (712.23%) (33.15%)
Free cash flow yield (116.45%) (477.81%) (25.50%)

Profitability

Metric CDIO LGVN Biotechnology median
Gross margin 100.00% 69.76% 65.16%
Operating margin (44,230.82%) (1,992.84%) 0.00%
Net margin (44,312.33%) (1,977.59%) 0.00%
Free cash flow margin (39,893.15%) (1,755.69%) 0.00%
Return on equity (75.44%) (203.61%) (56.36%)
Return on assets (70.62%) (145.64%) (48.04%)
Return on invested capital (219.40%) (4,549.04%) 0.00%

Growth

Metric CDIO LGVN Biotechnology median
Revenue growth (TTM) (25.13%) (42.74%) 6.02%
EPS growth (last fiscal year) 60.15% 50.76% 30.26%
Revenue growth, 5-year CAGR — (26.60%) 9.41%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric CDIO LGVN Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 17.15 2.63 4.72
Net debt to EBITDA 0.84 0.20 0.96

Dividend

Metric CDIO LGVN Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric CDIO LGVN Biotechnology median
Market cap 5.21m 4.79m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack